NSCLC with somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are associated with good responsiveness to tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib [9]. Here, EGFR is linked to non-small cell lung carcinoma.